Major air fryer manufacturers are focusing on innovative consumer-centric solutions to leverage key profit opportunities.

DUBAI, UAE / ACCESSWIRE / March 26, 2020 / The global air fryer market will grow at 6.8% CAGR through 2027, witnessing a very promising growth outlook during the forecast period (2019 – 2027). According to a new study by Future Market Insights (FMI), the market for air fryer is largely influenced by increasing health concerns, awareness about the benefits of lo-oil or oil free foods, and rising demand from the commercial sector.

"Key players will focus on product development, driven by advances in technology from manufacturers across the globe. In addition, new entrants will focus on economical technologies, to bolster their market position," reveals the FMI report.

Request report sample with 250+ pages to gain in-depth insights https://www.futuremarketinsights.com/reports/sample/rep-gb-11157

Key Research Findings

Digital air fryers will remain highly preferred devices through the forecast period, attributable to superior functionality.
Mid-range or economy air fryers will continue to witness healthy demand growth on the basis of sales.
Online sales platforms are also gaining traction owing to options of product comparisons, more designs, and lower prices.
Europe followed by North America will remain the leading regional markets through the forecast period, driven by rising consumer health awareness.

Key Growth Drivers

Rising health consciousness among consumers, and popularity of low-oil or oil-free foods plays a major role in the growth of market.
High demand from the commercial sector including restaurants and hotels contributes to global growth.
Advancements in tech functionalities such as temperature sensors, thermostat control and multiple cooking functions contribute to market growth.
Sales of new innovative air fryers supported by higher disposable incomes will drive adoption.

Key Impediments

The slower cooking times associated with air fryers will remain the key challenge for market players.

Explore the complete air fryer market report with 99 illustrative figures, 123 data tables, and the table of contents. Also find detailed market segmentation on https://www.futuremarketinsights.com/reports/sample/rep-gb-11157

Competition Structure Analysis – Air Fryer Market

The competition landscape of MEMS market remains moderately fragmented. Key producers are in vesting in online advertisements and celebrity endorsements to bolster brand awareness. Manufacturers are also pushing for product launches and innovation with research and development efforts.

Some of the key players in the air fryer market include, but are not limited to Pigeon Corporation, Cuisinart, Stanley Black & Decker Inc., Avalon Bay, DOMU Brands Ltd., Groupe SEB, NuWave LLC, Koninkllijke Philips N.V., TTK Prestige Ltd., De'Longhi S.p.A., GoWISE USA, Tefal, Breville, SharkNinja Operating LLC, and DASH.

Explore Future Market Insights' detailed coverage on,

Male Color Cosmetics Market– This research report provides an in-depth range of insights which identify revenue sectors, key strategies, and potential growth opportunities, associated with male color cosmetics.

Herbal Beauty Products Market– This report includes a detailed analysis on competitive scenarios, and essential information on major players in the Europe and Asia Pacific herbal beauty products market.

Shisha Tobacco Market– This write up encompasses detailed secondary research, which is used to estimate key industry players, overall size of the shisha tobacco market, and relevant industry associations.

Gain access to Market Ngage, an AI-powered, real-time business intelligence platform that goes beyond the conventional research solutions to solve the complex strategy challenges that organizations face today.

About the Report

This report offers global, regional, and national level analysis on the latest trends in the industry influencing the market. The study provides actionable insights on the air fryer market on the basis of product type (manual and digital), end use (household and commercial), sales channel (direct sales, supermarket/hypermarket, department stores, specialty stores, online, and others), price (high and mid-range/economy) across 30 countries spanning six key regions (North America, Latin America, Europe, East Asia, South Asia & Pacific, and MEA).

About Future Market Insights (FMI)

Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in London, the global financial capital, and has delivery centres in the U.S. and India. FMI's latest market research reports and industry analysis help businesses navigate challenges and take critical decisions with confidence and clarity amidst breakneck competition.

Contact:

Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
MARKET ACCESS DMCC Initiative
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Market Report: https://www.futuremarketinsights.com/reports/air-fryer-market
Press Release Source: https://www.futuremarketinsights.com/press-release/air-fryer-market

SOURCE: Future Market Insights

ReleaseID: 582674

CHARLOTTESVILLE, VA / ACCESSWIRE / March 26, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL)(NASDAQ:ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that it received an Issue Notification for the issuance of a patent by the United States Patent and Trademark Office (USPTO) for the treatment of Opioid Use Disorder (OUD) with its lead drug candidate, AD04, in people that are positive for select genotypes identified using the Company's propriety companion genetic test.

The patent is scheduled to issue as U.S. Patent Number 10,603,307 on March 31, 2020. Including the patent term adjustment provided in the Issue Notification, the patent is expected to provide commercial exclusivity for AD04 until September 2031, plus potential Hatch-Waxman extensions. Claim 1 of the patent provides for a method of treating an OUD, comprising administering to a patient in need thereof a therapeutically effective amount of AD04, wherein the patient is known to have certain genetics related to the serotonin system; AD04's primary mechanism of action is through the blockage of the serotonin-3 receptor.

"We continue to expand our activities around AD04, which we believe represents a potentially attractive treatment option for patients with OUD, since the physiology and neuro-transmitters involved in opioid addiction are similar to alcohol and could be expected to be modulated by a serotonin-3 receptor antagonist," said William Stilley, Chief Executive Officer of Adial Pharmaceuticals. "Similar to alcohol use disorder, OUD is a massively underserved market. The NIH and CDC report that almost 50,000 people in the U.S. died of opioid overdose in 2017, and the President's Council of Economic Advisors report from 2017 estimates the cost of the opioid epidemic to be more than half a trillion dollars annually in the U.S. alone. Adding this patent to our patent estates continues to enhance and strengthen our patent portfolio around AD04 and is an important milestone since AD04 has the potential to treat a variety of addictive disorders, including OUD. It is also another important step in building Adial into a leading pharmaceutical company focused on treating the terrible affliction of addiction."

About Adial Pharmaceuticals, Inc.

Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions. The Company's lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) and is currently being investigated in the Company's ONWARD Phase 3 pivotal clinical trial for the potential treatment of AUD in subjects with certain target genotypes, which are to be identified using the Company's proprietary companion diagnostic genetic test. A Phase 2b clinical trial of AD04 for the treatment of AUD showed promising results in reducing frequency of drinking, quantity of drinking and heavy drinking (all with statistical significance), and no overt safety concerns (there were no statistically significant serious adverse events reported). AD04 is also believed to have the potential to treat other addictive disorders such as opioid use disorder, gambling, and obesity. www.adialpharma.com

Forward Looking Statements

This communication contains certain "forward-looking statements" within the meaning of the U.S. federal securities laws. Such statements are based upon various facts and derived utilizing numerous important assumptions and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Statements preceded by, followed by or that otherwise include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could" are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. The forward-looking statements include statements regarding the new patent providing commercial exclusivity for AD04 until September 2031, plus potential Hatch-Waxman extensions, AD04 representing a potentially attractive treatment option for patients with OUD, the physiology and neuro-transmitters involved in opioid addiction being modulated by a serotonin-3 receptor antagonist and the potential of AD04 to treat other addictive disorders such as opioid use disorder, gambling, and obesity. Any forward-looking statements included herein reflect our current views, and they involve certain risks and uncertainties, including, among others, our ability to maintain commercial exclusivity for AD04 until September 2031, plus potential Hatch-Waxman extensions, the ability of AD04 to become attractive treatment option for patients with OUD, our ability to modulate the physiology and neuro-transmitters involved in opioid addiction with a serotonin-3 receptor antagonist, pour ability to expand the use of AD04 for use in patients with opioid use disorder, gambling and obesity, the ability of AD04 therapy to perform as designed, to demonstrate safety and efficacy, as well as results that are consistent with prior results, the ability to enroll patients and complete the clinical trials on time and achieve desired results and benefits, our ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements, regulatory limitations relating to our ability to promote or commercialize our product candidates for specific indications, acceptance of its product candidates in the marketplace and the successful development, marketing or sale of products, our ability to maintain our license agreements, the continued maintenance and growth of our patent estate, our ability to establish and maintain collaborations, our ability to obtain or maintain the capital or grants necessary to fund its research and development activities, and our ability to retain our key employees or maintain our Nasdaq listing. These risks should not be construed as exhaustive and should be read together with the other cautionary statement included in our Annual Report on Form 10-K for the year ended December 31, 2019, subsequent Quarterly Reports on Form 10-Q and Current reports on Form 8-K filed with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was initially made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise, unless required by law.

Contact:

Crescendo Communications, LLC
David Waldman / Natalya Rudman
Tel: 212-671-1021
Email: dwaldman@crescendo-ir.com

SOURCE: Adial Pharmaceutical, Inc.

ReleaseID: 582671

NEW YORK, NY / ACCESSWIRE / March 26, 2020 / Celsion Corp. (NASDAQ:CLSN) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 26, 2020 at 11:00 AM Eastern Time.

To listen to the event live or access a replay of the call – visit
https://www.investornetwork.com/event/presentation/60887

To receive updates for this company you can register by emailing info@investornetwork.com or by clicking get investment info from the company's profile.

About Investor Network

Investor Network (IN) is a financial content community, serving millions of unique investors market information, earnings, commentary and news on what's trending. Dedicated to both the professional and the average traders, IN offers timely, trusted and relevant financial information for virtually every investor. IN is an Issuer Direct brand, to learn more or for the latest financial news and market information, visit www.investornetwork.com. Follow us on Twitter @investornetwork.

SOURCE: Investor Network

ReleaseID: 582631

NEW YORK, NY / ACCESSWIRE / March 26, 2020 / Blueknight Energy Partners LP – PRF PERPETUAL USD – Ser A (NASDAQ:BKEP) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 26, 2020 at 11:00 AM Eastern Time.

To listen to the event live or access a replay of the call – visit
https://www.investornetwork.com/event/presentation/60569

To receive updates for this company you can register by emailing info@investornetwork.com or by clicking get investment info from the company's profile.

About Investor Network

Investor Network (IN) is a financial content community, serving millions of unique investors market information, earnings, commentary and news on what's trending. Dedicated to both the professional and the average traders, IN offers timely, trusted and relevant financial information for virtually every investor. IN is an Issuer Direct brand, to learn more or for the latest financial news and market information, visit www.investornetwork.com. Follow us on Twitter @investornetwork.

SOURCE: Investor Network

ReleaseID: 582630

NEW YORK, NY / ACCESSWIRE / March 26, 2020 / REX American Resources Corp. (NYSE:REX) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 26, 2020 at 11:00 AM Eastern Time.

To listen to the event live or access a replay of the call – visit
https://www.investornetwork.com/event/presentation/60870

To receive updates for this company you can register by emailing info@investornetwork.com or by clicking get investment info from the company's profile.

About Investor Network

Investor Network (IN) is a financial content community, serving millions of unique investors market information, earnings, commentary and news on what's trending. Dedicated to both the professional and the average traders, IN offers timely, trusted and relevant financial information for virtually every investor. IN is an Issuer Direct brand, to learn more or for the latest financial news and market information, visit www.investornetwork.com. Follow us on Twitter @investornetwork.

SOURCE: Investor Network

ReleaseID: 582629

NEW YORK, NY / ACCESSWIRE / March 26, 2020 / Partner Communications Co. Ltd. (NASDAQ:PTNR) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 26, 2020 at 11:00 AM Eastern Time.

To listen to the event live or access a replay of the call – visit
https://www.investornetwork.com/event/presentation/60603

To receive updates for this company you can register by emailing info@investornetwork.com or by clicking get investment info from the company's profile.

About Investor Network

Investor Network (IN) is a financial content community, serving millions of unique investors market information, earnings, commentary and news on what's trending. Dedicated to both the professional and the average traders, IN offers timely, trusted and relevant financial information for virtually every investor. IN is an Issuer Direct brand, to learn more or for the latest financial news and market information, visit www.investornetwork.com. Follow us on Twitter @investornetwork.

SOURCE: Investor Network

ReleaseID: 582628

BOSTON, MA / ACCESSWIRE / March 26, 2020 / Thornton Law Firm LLP announces that a class action lawsuit has been filed against AnaptysBio, Inc. on behalf of ANAB shareholders (NASDAQ:ANAB). Investors who have purchased at least 1,000 shares of ANAB stock between October 10, 2017 and November 7, 2019 are encouraged to submit their information at https://www.tenlaw.com/cases/ANAB to learn more about the lead plaintiff process. Shareholders may also contact the Thornton Law Firm at shareholder@tenlaw.com, or call 617-531-3917. There is no minimum number of shares required to be a class member.

FOR MORE INFORMATION, VISIT: https://www.tenlaw.com/cases/ANAB

The lawsuit alleges that AnaptysBio made misleading statements regarding the efficacy of etokimab, a drug for inflammatory diseases. The case alleges that AnaptysBio hyped data from their Phase 2a trial in peanut allergies as showing a "remarkable efficacy result" and described the drug as having a "pretty profound efficacy" in its treatment of patients with atopic dermatitis based on AnaptysBio's Phase 2a trial data for that indication. The lawsuit alleges that AnaptysBio provided misleading clinical trial data which failed to disclose key information and used questionable analysis, making the trial results regarding etokimab's efficacy and its prospects appear far better than they were. It is alleged that shareholders lost significant value as a result of these misstatements when the truth was disclosed beginning in November 2019.

Investors who purchased at least 1,000 shares of ANAB stock (NASDAQ: ANAB) are encouraged to contact the Thornton Law Firm's shareholder rights team at www.tenlaw.com/cases/ANAB, by email at shareholder@tenlaw.com, or calling 617-531-3917 to discuss the lead plaintiff process.

Interested ANAB shareholders have until May 26, 2020 to apply to be lead plaintiff. The lawsuit alleges violations of the federal securities laws, and the class has not yet been certified. Until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member. There is no minimum amount of shares required to be able to participate as a class member.

FOR MORE INFORMATION: https://www.tenlaw.com/cases/ANAB

Thornton Law Firm's securities attorneys are highly experienced in representing individual shareholders and institutional investors in recovering damages caused by violations of the securities laws. Its attorneys have established track records litigating securities cases in courts throughout the country and recovering losses on behalf of shareholders. This may be considered Attorney Advertising in some jurisdictions. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

CONTACT:
Thornton Law Firm LLP
State Street Financial Center
1 Lincoln Street
Boston, MA 02111

SOURCE: Thornton Law Firm LLP

ReleaseID: 582673

OwnerInsight provides a no-cost, nationwide solution to maintain proper social distancing while giving lenders, appraisers, and AMCs timely information from inside homes they are unable to physically enter because of COVID-19

RENO, NV / ACCESSWIRE / March 26, 2020 / Clear Capital, the premier provider of modern real estate valuation and analytics technology solutions, today announced OwnerInsight™, a tool that enables safe social distancing while empowering homeowners to provide timely, high-quality information and images of the interior and exterior of their homes to lenders, appraisers, and appraisal management companies (AMCs) through a secure interface.

OwnerInsight will launch the week of March 30 and is being offered for free in response to the COVID-19 health situation. OwnerInsight works seamlessly on camera-enabled mobile devices with no need for app downloads, and photo metadata is captured to ensure protection against fraud. Clear Capital developed OwnerInsight for the mortgage industry in response to the Federal Housing Finance Agency (FHFA), Fannie Mae, and Freddie Mac's temporary approval of alternative appraisal products that reduce the frequency of in-person interaction to mitigate the spread of COVID-19.

OwnerInsight ensures appraisers have vital information to complete accurate appraisals while also allowing homeowners and appraisers to comply with social distancing guidelines. In response to the COVID-19 health situation, Clear Capital is providing free, live support for OwnerInsight users from 6 a.m. to 6 p.m. PT on weekdays and from 7 a.m. to 4 p.m. PT on weekends.

"OwnerInsight walks homeowners through a logical, easy-to-follow process of taking photos and answering a few questions about the quality, condition, and unique characteristics of their home," said Duane Andrews, CEO and Co-Founder of Clear Capital. "In order to provide easy accessibility to this helpful and timely technology, we are currently providing OwnerInsight, along with help desk phone support, at no cost to all lenders, appraisers, and AMCs."

According to Andrews, the goal with OwnerInsight is to promote safe social distancing while helping provide the appraiser with adequate and sufficient information as referenced in question 15 of Fannie Mae's "COVID-19 Frequently Asked Questions" document.

Lenders, AMCs, and tech platforms can build API connections to enable OwnerInsight within their workflows. All that is required to initiate an order with the API is a property address and basic homeowner contact information.

"During the COVID-19 health situation, OwnerInsight provides critical efficiencies for lenders and appraisers to access information that is indispensable to the appraisal process," said Jeff Allen, Executive Vice President of Valuation Strategy at Clear Capital. "Without OwnerInsight on the market, homeowners and appraisers would face a manual and confusing back-and-forth, trapped in email and phone calls with unclear requirements and no fraud mitigation. We want to ensure the industry remains active and capital remains fluid during these difficult times."

Additionally, Clear Capital is partnering with Ellie Mae®, the leading loan origination platform provider for the residential mortgage industry, to make OwnerInsight seamlessly available to lenders who are on the Ellie Mae Digital Lending Platform via Encompass Partner Connect.

"During this unprecedented time, the need for innovative technology solutions that keep mortgage processes moving forward while limiting in-person interaction is critical," said Parvesh Sahi, Senior Vice President of Business Development at Ellie Mae. "Clear Capital's OwnerInsight will give our lenders the ability to connect homeowners and appraisers while ensuring a compliant and efficient mortgage process to solve both immediate and long-term lender needs."

Visit GetOwnerInsight.com for more information or to initiate an instant order via the web interface.

About Clear Capital:

Our story began in the mountain town of Truckee, California nearly 20 years ago, when we pioneered delightfully simple, web-based valuation technology solutions for an industry relying on paper. Today, we're grateful to call the nation's largest banks and financial institutions our customers. We've grown to more than 600 team members who share and embody our unwavering commitment to build a better way. As we continue our journey to modernize valuation, we'll hold on to our promise from day one: to go wherever it leads and do whatever it takes to serve our customers with remarkable technology and uncompromising service. Discover more at ClearCapital.com.

Media Contact:

Adam Gerber
Caliber Corporate Advisers for Clear Capital
adam@calibercorporateadvisers.com
917-985-6630, ext. 09

###

SOURCE: Caliber Corporate Advisers

ReleaseID: 582670

MIAMI, FL / ACCESSWIRE / March 26, 2020 / Hemp Naturals Inc. (OTC PINK:HPMM) has proudly announced that it has recently launched an all-new line of Premium CBD products in the market. These new products will now be available at Tobacco Town, Located at 2500 East Hallandale Beach Blvd Suite La, Hallandale Beach FL 33009 this week onwards and they're a great addition to the growing availability of our CBD Gummies.

CBD is basically a superfood that when taken regularly, provides a broad host of amazing physiological benefits. Also, each product is handcrafted and proudly made in the USA. "Our hand-crafted CBD Gummies are FDA audited and are produced in a GMP compliant facility with pure Colorado hemp CBD." The spokesperson added. Each product manufactured by the company is not only all-natural but also organic, gluten free and non-GMO. Furthermore, precisely 25mg of hemp extract is used per gummy and these products are also third-party tested and are certified for being free of any kind of THC, chemicals and pesticides.

This is a very exciting time for CBD companies to begin exploring new ways to improve the lives of those in our communities at Hemp Naturals. We are experiencing the start of a new age in this country, when people's access to an improved quality of life is going to change dramatically through everyday products, and we are blessed and thrilled to help carry Florida into that future.

Cautionary Language Concerning Forward-Looking Statements:

This release contains "forward-looking statements" that include information relating to future events and future financial and operating performance. The words "may," "would," "will," "expect," "estimate," "can," "believe," "potential," and similar expressions and variations thereof are intended to identify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which that performance or those results will be achieved. Forward-looking statements are based on information available at the time they are made and/or management's good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Important factors that could cause these differences include, but are not limited to: fluctuations in demand for Hemp Naturals products, the introduction of new products, the Company's ability to maintain customer and strategic business relationships, the impact of competitive products and pricing, growth in targeted markets, the adequacy of the Company's liquidity and financial strength to support its growth, and other information that may be detailed from time-to-time in Hemp Naturals filings with the United States Securities and Exchange Commission. Examples of such forward-looking statements in this release include statements regarding future sales, costs and market acceptance of products as well as regulatory actions at the State or Federal level. For a more detailed description of the risk factors and uncertainties affecting Hemp Naturals please refer to the Company's Securities and Exchange Commission filings, which are available at www.sec.gov. Hemp Naturals undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT:

Hempofnaturals@gmail.com
Hempofnaturals.com
Levi Jacobson

SOURCE: Hemp Naturals Inc.

ReleaseID: 582535

CORAL GABLES, FL / ACCESSWIRE / March 26, 2020 / The top website for all things gold stocks, GoldStocks.com just released a new & exclusive article titled: Time To Buy Gold Stocks? 4 Names To Know. The team at GoldStocks.com talks about 4 gold stocks to watch on March 26th.

Within this article, GoldStocks.com discusses how: "Many gold companies seem to be weathering the recent virus storm quite well. As operations for mining have been limited, things like milling and production appear to be continuing. So where some may assume the virus could impact all industries negatively, the unique circumstances could make gold potential more attractive. So what's next for gold? Well, with the "unlimited quantitative easing" in play, the bullish signal could have just been given to gold. Thursday, we've already started to see a surge in gold prices and gold stocks to watch including Newmont Corporation (NEM)."(click here for the full article)

Read the article from GoldStocks.com titled: Time To Buy Gold Stocks? 4 Names To Know<<< Click Here

Gold Stocks (GoldStocks.com)

GoldStocks.com is the best place to find the top gold stocks to buy, a full list of gold stocks and mining stock news, articles & information. Mining stocks and Gold Stocks are off to a very strong start in 2020 and are expected to continue their bullish run. Subscribe, to our Free Gold Stocks Newsletter and stay updated on the top gold stocks picks, exclusive articles, gold stock alerts and mining company news.

Contact:

Name: Adam Lawrence
Email: news@goldstocks.com
Phone: (305) 390-2368

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. MIDAM VENTURES LLC, which owns www.GoldStocks.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. Please Read Our Full Disclosure Located Here: https://goldstocks.com/disclaimer/

SOURCE: GoldStocks.com

ReleaseID: 582675